Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Apr 8, 2021

Keywords

ClinConnect Summary

The CUSHINGOMICS clinical trial is studying how different people respond to glucocorticoids, which are hormones that can be too high or too low in the body. This can lead to Cushing's syndrome, where patients may experience issues like weight gain in specific areas, muscle loss, diabetes, high blood pressure, or weak bones. The trial aims to find specific markers in the blood and urine that can help predict who might develop these complications, as well as markers that indicate how well people with adrenal insufficiency are managing their condition.

To participate, individuals must be aged 65 or older and fall into one of several groups: those with excess glucocorticoids from either natural causes or medication, those with chronic adrenal insufficiency, or those without glucocorticoid excess but who have diabetes, high blood pressure, or weak bones. Participants will have their blood and urine tested to help researchers identify the factors that determine how sensitive each person is to glucocorticoids. The trial is currently recruiting and aims to include 600 participants in total. If you choose to participate, you will help advance our understanding of these conditions and how to better predict and manage them for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • an endogenous hypercortisolism (group 1)
• • a disease justifying the next start of glucocorticoid therapy (group 2)
• • chronic adrenal insufficiency (group 3)
• • subjects with either diabetes, hypertension or osteoporosis, but without glucocorticoid excess (control group)
• • patients will have to be affiliated to a social security scheme
• • patients should be able to understand the study and able to express their consent
• Exclusion Criteria:
• • patients with reduced life expectancy, less than 2 years
• • pregnant or lactating women
• • patients refusing the protocol
• • patients under state medical assistance